External quality assessment (EQA) scheme on PCR for Bordetella pertussis, 2012 on behalf of the EUpert-labnet network
ECDC is publishing the first external quality assurance scheme (EQA) for Bordetalla pertusis PCR, participated by 21-one laboratories from 21 European Union/European Economic Area countries.
Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation
This report summarises the results from two epidemiological studies conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium undertaken in eight European Union (EU)/European Economic Area (EEA) countries in order to investigate a possible association between an unexpected increase in narcolepsy cases following the use of influenza A(H1N1)pdm09 vaccines. Narcolepsy is an underdiagnosed disease of widely unknown etiology.
Technical report In Brief: Narcolepsy in association with pandemic influenza vaccination
This report summarises the results from two epidemiological studies to investigate a possible association between an unexpected increase in narcolepsy cases following the use of the influenza A(H1N1)pdm09 vaccines. The studies were conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium under the auspices of ECDC and undertaken in Denmark, Finland, France, Italy, the Netherlands, Norway, Sweden and the United Kingdom. This Technical Report In Brief accompanies the full Report ‘Narcolepsy in association with pandemic influenza vaccination- A multi-country European epidemiological investigation’.
Review of outbreaks and barriers to MMR vaccination coverage among hard to reach populations in European countries
In recent years, substantial progress had been made towards eliminating measles, mumps and rubella in Europe. Measles vaccine coverage is on the rise and measles cases decreasing in many countries. However, there have still been several large outbreaks of measles, mumps and rubella reported in European countries.
External quality assurance scheme for Haemophilus influenzae 2011
The results of this external quality assurance distribution have shown that European Haemophilus reference laboratories differ in the level of characterisation of strains, ranging from simple speciation to full identification and typing. All but two laboratories routinely phenotypically serotype isolates. Fifteen laboratories (52%) performed PCR-based capsular genotyping, 23 laboratories (79%) reported antimicrobial susceptibility testing results.
External quality assessment scheme 2011 for Neisseria meningitidis
This report on EQA performance shows that European Reference Laboratories for Meningococci differ in their capacities and the level of characterisation of the distributed N. meningitidis material, but that there have been improvements since the first ECDC IBD-labnet distribution.
External Quality Assurance scheme for Haemophilus influenzae, 2012
In May 2012 a collection of five strains of Haemophilus spp was sent to 28 participating reference laboratories in the IBD-labnet surveillance network for quality assurance testing. The laboratories were asked to characterise the five strains by performing standard laboratory protocols for the methods usually used by the laboratory for: species identification, biotyping and serotyping by serological methods and/or PCR.
The results of this EQA are published in the this report.
Implementation of the Council Recommendation on seasonal influenza vaccination
In support of the EU Council Recommendation of December 2009 on seasonal influenza vaccination, this technical report provides data on vaccination policies and strategies, vaccination coverage data, and data on barriers to vaccination for seasonal influenza in the EU/EEA countries.
Infant and children seasonal immunisation against influenza on a routine basis during inter-pandemic period
Annual influenza vaccination of risk groups has been common practice in Europe and elsewhere for many years. Routine influenza immunisation of healthy children has been recommended in some countries, to reduce morbidity among children with the potential additional benefit of reducing the spread of disease and thus indirectly protect adults at high risk of severe influenza.
Measles and rubella elimination: communicating the importance of vaccination
The goal of this project is to support EU Member States in their fight against measles and rubella. This report should enable Member States to engage in effective, evidence-based risk communication.